Participants may receive a combination of the study drug pumitamig (also referred to as BNT327) and chemotherapy. The chemotherapy medications involved include oxaliplatin, fluorouracil, and capecitabine, sometimes used alongside calcium folinate. In the first part of the study, two different doses of pumitamig are tested to see which one works best. In the second part, the more effective dose is compared to a standard treatment consisting of nivolumab and chemotherapy.

The study is conducted in stages. Initially, the goal is to determine which dose of the new medicine is most effective at controlling tumor growth while minimizing side effects. Following this, the selected dose is evaluated to see if it can extend progression-free survival, which is the length of time a patient lives with the disease without it getting worse, and overall survival, which is the total length of time a patient remains alive.

The purpose of the study is to determine whether using this special contrast-enhanced imaging technique can provide better information about cancer spread to lymph nodes compared to standard imaging methods. This is important both before and after patients receive initial cancer treatment with chemotherapy and radiation therapy.

During the study, participants will receive a single dose of Ferrotran through an infusion into their vein. The amount given depends on the person’s weight. They will then undergo MRI scanning to create detailed images of the lymph nodes. The imaging procedure will be performed twice – once before starting cancer treatment and once after completing it. The total duration of participation in the imaging part of the study is 2 days.

The treatment involves a combination of several cancer medications administered through intravenous infusion. These medications include fluorouracil, docetaxel, oxaliplatin, carboplatin, paclitaxel, and folinic acid. These drugs work together to kill cancer cells or stop them from growing. The medications will be given in specific sequences and combinations over several weeks.

The study will examine how well patients respond to this treatment by measuring how long they remain free from cancer progression. The treatment plan includes giving these medications before surgery, which is different from traditional approaches where some treatments are given after surgery. This approach aims to potentially improve outcomes for patients with this type of cancer.

The purpose of this research is to determine how well ivonescimab works when combined with chemotherapy in treating patients with advanced stomach and esophageal junction cancers. The study includes patients whose cancers may have specific biological markers (HER2, PD-L1, or Claudin18.2). These markers are proteins found on cancer cells that can affect how the cancer responds to treatment.

During the study, participants will receive ivonescimab through an intravenous infusion along with their chemotherapy treatment. The treatment will continue as long as patients show benefit from it and do not experience unacceptable side effects. Regular medical examinations and scans will be performed to monitor how the cancer responds to the treatment combination.

The purpose of this research is to understand how safe AZD4360 is and how well it works in treating these types of cancer. The study will also examine how the medication moves through the body over time. The medication will be given to patients whose cancer has a specific characteristic called CLDN18.2 expression and who have already received at least one previous treatment for their cancer.

This is a combined Phase 1 and Phase 2 study, which means it will first determine the safest dose of the medication and then test how effective it is at treating these cancers. During the study, participants will receive AZD4360 and undergo various medical assessments to monitor their health and the medication’s effects. The treatment will continue as long as patients are benefiting from it and not experiencing unacceptable side effects.

The purpose of the study is to evaluate how well the new combination works as a first-line treatment for patients with this type of cancer. Participants in the study will be randomly assigned to receive either the new combination or the standard treatment. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure the results are unbiased. The study will take place over a period of time, with regular assessments to monitor the progress and health of the participants.

Throughout the study, researchers will focus on key outcomes such as progression-free survival, which measures how long patients live without the cancer getting worse, and overall survival, which measures how long patients live overall. The study will also look at the safety of the treatments and any side effects that may occur. By the end of the study, the goal is to determine if the new treatment combination offers a better option for patients with this type of cancer.

The purpose of the study is to evaluate how well the 68Ga-FAPI-46 PET imaging works in detecting gastrointestinal cancers. Participants in the study will undergo this imaging process, which is designed to provide clear pictures of the cancerous regions. The study will compare the results of this new imaging method with previous standard imaging techniques to see if it offers better detection of cancer locations.

Throughout the study, the safety of the 68Ga-FAPI-46 PET imaging will be monitored, including any side effects that may occur. The study will also assess how the imaging results might influence treatment decisions made by doctors. This research aims to improve the understanding of how effective this imaging method is in identifying and managing gastrointestinal cancers.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

The treatment plan combines several medications. Patients will receive pembrolizumab, which helps the immune system fight cancer cells, along with chemotherapy drugs including fluorouracil, oxaliplatin, and capecitabine. These medications will be given together with Trazimera (trastuzumab), which specifically targets HER2-positive cancer cells.

Most medications in this study will be given through an intravenous infusion directly into the bloodstream, while some will be taken as tablets by mouth. The treatment will continue as long as it remains beneficial for the patient and side effects are manageable. Doctors will regularly monitor the patient’s heart function and overall health throughout the treatment period.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to see if the new combination of domvanalimab and zimberelimab with chemotherapy can help people live longer compared to the treatment with nivolumab and chemotherapy. Participants in the study will be randomly assigned to receive either the new combination treatment or the nivolumab treatment. The study will last for up to 24 months, during which participants will receive their assigned treatment and be monitored regularly by the study team. The study will also look at how the treatments affect the participants’ quality of life and any side effects they may experience.

In addition to the main goal of comparing how long participants live with each treatment, the study will also look at other important factors. These include how long it takes for the cancer to start growing again, how many participants experience a reduction in their cancer size, and how long these reductions last. The study will also monitor any side effects or adverse events that participants may experience during the trial. This information will help researchers understand the safety and effectiveness of the new treatment combination.

Participants in the study will receive treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor the participants over time to assess how well they tolerate the treatment and to observe any changes in their cancer. The trial will also look at how the body processes AZD0901 and whether the immune system reacts to it. The study aims to gather information on the overall survival of participants, how long they live without the cancer getting worse, and how long any positive response to the treatment lasts.

Throughout the study, researchers will collect data on the size of the tumors and any changes that occur. They will also investigate the relationship between certain genetic or protein markers in the tumors and the effectiveness of the treatment. This information will help determine if AZD0901 could be a beneficial treatment option for patients with these types of cancers. The study is expected to continue until 2027, with recruitment of participants starting in late 2024.

Participants in the study will receive treatment with nivolumab and radiation therapy. The study will monitor the safety of this treatment by observing any side effects and changes in health indicators such as blood tests and vital signs. The study will also assess how well the treatment can be carried out and how patients respond to it. The trial is designed to gather information over a period of time to understand the potential benefits and risks of this treatment approach.

The study aims to provide insights into the overall survival of patients, which refers to the time from the start of treatment until death from any cause. It will also look at how the cancer responds to treatment both within the area that receives radiation and outside of it. For some participants, the study will measure how long they live without the cancer getting worse or coming back after surgery. Additionally, the study will evaluate the quality of life of participants using questionnaires. The trial is expected to continue until the end of 2025.

The purpose of this study is to evaluate how effective nivolumab is when used during a period of active surveillance. Active surveillance is a way of monitoring a patient’s condition without giving any treatment unless there are changes in test results that show the disease is getting worse. In this study, patients who have shown a complete response to the initial treatment will receive nivolumab to see if it helps keep the cancer from coming back.

Participants in the study will receive nivolumab through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor patients over a period of time to see how long they remain free of cancer and to observe any side effects that may occur. The goal is to understand if nivolumab can help improve outcomes for patients with esophageal cancer who are in active surveillance after their initial treatment.

The purpose of the study is to understand how the uptake of [18F]F-AraG changes in tumor lesions after radiotherapy. This will help researchers learn more about how cancer cells respond to treatment. Participants in the study will receive radiotherapy and will undergo imaging scans to track the uptake of the imaging agent in their tumors. These scans will be done at different times to see how the uptake changes over time.

Throughout the study, participants will continue their ongoing treatment with immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer. The study aims to provide valuable insights into the effectiveness of radiotherapy in combination with immunotherapy by using the [18F]F-AraG imaging agent to monitor changes in the cancer cells. This research could lead to better understanding and improvements in cancer treatment strategies.

The purpose of the study is to see how well these new treatments work in helping patients live longer. Participants in the study will be randomly assigned to receive either RO7121661, RO7247669, or nivolumab. The study is designed to be “blinded,” meaning that neither the participants nor the researchers will know which treatment each participant is receiving, to ensure unbiased results. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatments more accurately.

Throughout the study, participants will receive their assigned treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants’ overall health and any side effects they may experience. The goal is to determine which treatment is most effective in improving survival and quality of life for people with this type of esophageal cancer. The study will continue for a period of time to gather enough information to make a clear comparison between the treatments.

Participants in the study will receive the treatment intravenously, which means the medication will be given through a vein. The study will take place over a period of time, during which patients will receive the combination of Avelumab and chemotherapy drugs. The researchers aim to determine if this combination can lead to a complete response, meaning no remaining cancer cells, in the resected (surgically removed) cancer tissue. The study will also look at other outcomes, such as overall survival and disease-free survival, to understand the long-term effects of the treatment.

The trial is designed to provide valuable information on whether this new combination of treatments can offer better results compared to traditional chemotherapy alone. By participating in this study, researchers hope to gather data that could lead to improved treatment options for patients with Gastric cancer and Gastroesophageal Junction cancer. The study is conducted under strict guidelines to ensure the safety and well-being of all participants.

Nivolumab, also known by its code name BMS-936558, is given as an infusion, which means it is administered directly into the bloodstream through a vein. The study will observe patients over a period to see if the cancer returns or if they remain disease-free. The main goal is to see how long patients can live without the cancer coming back, which is referred to as disease-free survival. Additionally, the study will look at overall survival, which is the length of time patients live after starting the study, regardless of whether the cancer returns.

Participants in the study will receive either nivolumab or a placebo, and neither the patients nor the researchers will know which treatment each patient is receiving. This is known as a double-blind study, which helps ensure that the results are not influenced by expectations about the treatment. The study aims to provide valuable information on whether nivolumab can help prevent the return of esophageal or gastroesophageal junction cancer after surgery.

The purpose of this study is to evaluate how effective the treatment is in reducing the risk of infections after esophagectomy. Participants in the study will receive the treatment for a period of up to seven days. The study will monitor the occurrence of infections, such as pneumonia, within 30 days after surgery. The trial will also look at other possible complications, including infections in different parts of the body, leakage at the surgical site, and overall recovery after surgery.

Throughout the study, researchers will collect information on the health and recovery of participants, including their quality of life and any additional surgeries or hospital stays needed. The study aims to provide valuable insights into improving the care and outcomes for patients undergoing surgery for esophageal cancer.

Participants in the study will receive either tocilizumab or a placebo, in addition to their regular cancer treatment. The study will monitor how well the cancer responds to the treatment by looking at changes in the tumor tissue. This will help researchers understand if tocilizumab can make the standard treatment more effective. The study will also look at other factors, such as the rate of successful tumor removal through surgery and the overall survival of participants.

Throughout the study, researchers will collect information on the safety of tocilizumab, including any side effects or complications that may arise. They will also measure certain proteins and genes in the blood and tumor tissue to understand how tocilizumab works in the body. The study aims to provide valuable insights into whether tocilizumab can be a beneficial addition to the treatment of esophageal adenocarcinoma.

The purpose of the study is to evaluate the safety and effectiveness of this combination therapy. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study is divided into two phases. The first phase, known as Phase 1b, will focus on determining the safest dose of S095029 when used in combination with Keytruda. The second phase, Phase 2, will assess how well the treatment works in shrinking tumors and controlling the cancer. Throughout the study, researchers will monitor participants for any side effects and changes in their health to ensure the treatment is safe and effective.

This trial is open-label, meaning both the participants and the researchers know which treatments are being administered. The study is expected to continue for several years, allowing researchers to gather comprehensive data on the treatment’s impact on cancer progression and patient well-being. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to collect valuable information on the treatment’s effects.

The purpose of the study is to evaluate how these imaging agents can show changes in T cells and their activation in response to immunotherapy, a type of cancer treatment that helps the immune system fight cancer. The study will involve patients with NSCLC who are scheduled to have surgery after receiving chemotherapy and immunotherapy. The imaging agents will be used to take pictures of the tumors and areas rich in T cells, like lymph nodes, before surgery. This will help researchers see how well the imaging agents can detect T cell activity and changes in the tumors.

Throughout the study, participants will receive the imaging agents and undergo imaging scans to capture detailed pictures of their tumors and T cell-rich areas. These scans will help researchers understand the relationship between the presence of T cells and the changes in the tumors. The study aims to provide valuable insights into how the immune system interacts with cancer and how imaging can be used to monitor treatment responses in NSCLC.

The purpose of the study is to evaluate how effective durvalumab is when used alongside these treatments and then as a maintenance therapy, which means it is continued after the initial treatment to help keep the cancer from coming back. The study will compare the outcomes of patients receiving this combination of treatments to those receiving other standard treatments. Patients will receive the treatments over a period of time, and their progress will be monitored to see how well the cancer responds and how long they remain free from cancer progression.

Throughout the study, the safety of the treatments will be closely monitored, and any side effects will be recorded. The study will also assess the overall survival of patients, which refers to the length of time patients live after starting the treatment, regardless of whether the cancer progresses. Additionally, the quality of life of patients will be evaluated using questionnaires designed to understand how the treatments affect their daily lives and well-being. The study aims to provide valuable information on the potential benefits of combining radiochemotherapy and immunotherapy for treating unresectable esophageal cancer.

The purpose of this study is to find a suitable dose of zongertinib when used in combination with either trastuzumab deruxtecan or trastuzumab emtansine, and to see if these combinations can help people with these types of cancer. The study is divided into two main parts. The first part, called Phase Ib, involves gradually increasing the dose of zongertinib to determine the highest dose that can be given safely. The second part, Phase II, aims to find out how effective the treatment is at shrinking tumors or stopping them from growing. Participants will receive the study medications and be monitored for any side effects and how well the treatment is working.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their cancer. The study will help researchers understand the best way to use these medications together and whether they can provide a new treatment option for people with these advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to determine if the combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is better at delaying the progression of cancer compared to a regimen called FOLFOX, which includes fluorouracil, oxaliplatin, and folinic acid, with or without nivolumab. The study will follow patients over a period to monitor how their cancer responds to the treatment and to assess their overall health and quality of life. Patients will receive their assigned treatment and will be regularly monitored by healthcare professionals to track the progress of their disease and any side effects they may experience.

This trial aims to provide valuable information on the effectiveness and safety of these treatment combinations for patients with advanced gastric, esophageal, or gastroesophageal junction cancer. The results could help improve treatment options for these patients in the future.

The purpose of the study is to determine if taking aspirin regularly after standard cancer treatment can help prevent the cancer from coming back and improve the chances of survival. Participants in the study will be randomly assigned to receive either the aspirin or the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the aspirin and who is receiving the placebo. This helps ensure that the results are not influenced by expectations or bias.

Participants will take the study medication for a period of up to 60 months. Throughout the study, participants will be monitored for any side effects and for signs of cancer recurrence. The study will also look at other health outcomes, such as overall survival, adherence to the medication, and any serious health events that may occur. The goal is to gather information that could lead to better treatment strategies for preventing cancer recurrence and improving survival rates in patients with these types of cancers.

Participants in the study will receive the treatments through an intravenous method, which means the medications are given directly into a vein. The study is divided into two phases. In the first phase, different doses of the medications and radiation therapy will be tested to find the maximum dose that patients can tolerate. In the second phase, the effectiveness of the recommended dose will be assessed by checking the response of the cancer to the treatment after 12 weeks.

The study aims to find out if the combination of carboplatin, paclitaxel, and radiation therapy can lead to a complete response in the tumor, meaning the cancer is no longer detectable. The study will also monitor for any side effects and evaluate the overall health and quality of life of the participants during and after the treatment. The goal is to improve treatment options for elderly patients with esophagus cancer.

The purpose of this study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive the combination of these medications and will be monitored for any side effects and how their cancer responds to the treatment. The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The study aims to understand how well the combination of these medications can help in treating the different types of cancer mentioned.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers learn more about the potential benefits and risks of using Pembrolizumab, Lenvatinib, and Belzutifan together, which could lead to new treatment options for patients with these types of cancer in the future.

The purpose of the study is to determine if octreotide can help reduce weight loss after surgeries like gastrectomy or esophagectomy, which are procedures to remove part or all of the stomach or esophagus. Participants in the study will receive either octreotide or a placebo. The study will monitor participants over several months, checking their weight and other health indicators at regular intervals after surgery.

Throughout the study, various health aspects will be assessed, including body composition, quality of life, and the need for additional nutritional support. The study will also track any side effects experienced by participants, such as nausea or fatigue, to ensure the safety and effectiveness of the treatment. The trial aims to provide valuable insights into how octreotide can support recovery and improve outcomes for patients undergoing surgery for esophageal or gastric cancer.

Participants in the study will receive either pembrolizumab or a placebo, in addition to their regular cancer treatment. The study will last for a period of time during which participants will receive treatment and be monitored for any changes in their health. The study aims to understand how pembrolizumab affects the length of time participants live without the cancer getting worse and overall survival. The study will also look at any side effects that participants may experience during the treatment.

Other medications involved in the study include calcium folinate, folinic acid, fluorouracil, cisplatin, and oxaliplatin, which are commonly used in cancer treatment. These medications are given as solutions for infusion, meaning they are administered directly into the bloodstream through a vein. The study is designed to provide valuable information about the effectiveness and safety of pembrolizumab in treating esophageal carcinoma, potentially leading to improved treatment options for patients with this type of cancer.

The purpose of the study is to compare the new combination of treatments with the standard care currently used for this type of cancer. Participants in the study will receive either the new combination of treatments or the standard care. The study will be conducted in two parts. The first part will focus on evaluating the safety of the new treatment combination, while the second part will compare the overall survival of participants receiving the new treatment versus those receiving standard care. The study will involve regular monitoring and assessments to ensure the safety and well-being of participants.

Participants will receive the treatments over a period of time, with some treatments given as an intravenous infusion (a method of delivering medication directly into the bloodstream through a vein) and others taken orally as capsules. The study aims to provide valuable information on whether the new combination of treatments can improve outcomes for patients with metastatic esophageal carcinoma. The trial will also monitor any side effects experienced by participants to ensure the treatments are safe. The study is expected to continue until the end of 2025.